Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

被引：10
|
作者：
Crews, Kristine R. [1 ]
Caudle, Kelly E. [1 ]
Dunnenberger, Henry M. [2 ]
Sadhasivam, Senthilkumar [3 ,4 ]
Skaar, Todd C. [5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] NorthShore Univ Hlth Syst, Ctr Mol Med, Evanston, IL USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA
[5] Indiana Univ Sch Med, Div Clin Pharmacol, Dept Med, Indianapolis, IN 46202 USA
来源：
CLINICAL CHEMISTRY | 2015年 / 61卷 / 05期
关键词：
PHARMACOGENETICS; IMPLEMENTATION;
D O I：
10.1373/clinchem.2014.237412
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [41] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Doki, Kosuke
    Sekiguchi, Yukio
    Kuga, Keisuke
    Aonuma, Kazutaka
    Homma, Masato
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 257 - 262
  • [42] CYP2D6 genotype and response to neoadjuvant tamoxifen therapy: a prospective study in Japan
    Zembutsu, Hitoshi
    Nakamura, Seigo
    Akashi, Sadako
    Kuwayama, Takashi
    Watanabe, Chie
    Takei, Hiroyuki
    Ishikawa, Takashi
    Hasegawa, Yoshie
    Lee, Soo Chin
    Yu, Tan Ern
    Matsukata, Ayami
    Matsumoto, Hiroshi
    Kutomi, Goro
    Nakamura, Yusuke
    [J]. CANCER RESEARCH, 2015, 75
  • [43] In vitro O-demethylation of codeine-6-glucuronide by CYP2D6
    Schänzle, G
    Zanger, U
    Hofmann, U
    Mikus, G
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R174 - R174
  • [44] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [45] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [46] GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population
    Bank, Paul C. D.
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    van der Straaten, Tahar
    [J]. PHARMACOGENOMICS, 2015, 16 (07) : 681 - 687
  • [47] CYP2D6 HhaI genotype and the neuroleptic malignant syndrome
    Iwahashi, K
    Yoshihara, E
    Nakamura, K
    Ameno, K
    Watanabe, M
    Tsuneoka, Y
    Ichikawa, Y
    Igarashi, K
    [J]. NEUROPSYCHOBIOLOGY, 1999, 39 (01) : 33 - 37
  • [48] Effect of genotype and methylation of CYP2D6 on smoking behaviour
    Tiili, Emmi M.
    Antikainen, Miia S. H.
    Mitiushkina, Natalia V.
    Sukhovskaya, Olga A.
    Imyanitov, Evgeny N.
    Hirvonen, Ari P.
    [J]. PHARMACOGENETICS AND GENOMICS, 2015, 25 (11): : 531 - 540
  • [49] Estimating genotype and allele frequencies of the CYP2D6 gene
    Acuna, M.
    Eaton, Y. L.
    [J]. PHARMACOLOGICAL RESEARCH, 2016, 110 : 240 - 240
  • [50] Effect of CYP2D6 genotype on duloxetine serum concentration
    Hole, Kristine
    Gangso, Sofie
    Jensstuen, Asa Tonette
    Ormoy, Hanne Holte
    Paulsen, Maren
    Molden, Espen
    Haslemo, Tore
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (01) : 186 - 192
12345